Reassessing Stroke Prevention in Atrial Fibrillation Patients

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/59/7a/1e/597a1e41-e0fb-51e2-8a1f-ca2e5c72d904/mza_14009391667703168945.jpg/600x600bb.jpg

State of Health

Medzcool

69 episodes

3 days ago

Your quick, fun fix for all things medical! We're serving up the latest healthcare scoop in bite-sized episodes, perfect for on-the-go docs and medical pros. Stay in the know, get inspired, and let's shake up the healthcare world together!

Medicine

Health & Fitness

RSS

All content for State of Health is the property of Medzcool and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38371013/38371013-1688564859181-95e3003c65b01.jpg

Reassessing Stroke Prevention in Atrial Fibrillation Patients

State of Health

4 minutes 23 seconds

2 years ago

Reassessing Stroke Prevention in Atrial Fibrillation Patients

We explore the efficacy of the non-vitamin K antagonist edoxaban as an anticoagulant in patients with atrial high-rate episodes (AHREs) from the perspective of the NOAH-AFNET 6 trial. We discuss the intriguing results and what they might mean for current clinical practice in stroke prevention. Original article here.

ABOUT THE STATE OF HEALTH

The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠
Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠
Threads: ⁠threads.net/@medzcool